How we get to the forecast.

The practical operating path from launch to ≈ $134.7M by FY2031 — two revenue engines, quarter by quarter, with a named owner behind every workstream.

1. Operating thesis

E4L, Inc. is a new Salt Lake City company — a startup by design, launching with acquired assets and revenue from day one. Over the prior two decades the original UK business built the assets the Company acquired — the products, the IP, ~650 active practitioners (infoceutical wholesale ≈$3.5M/yr at close), and a dataset of 1M+ scans — but taking the vision mainstream, subscription-first and consumer-led, needed a new company: a US home, a clean structure, fresh capital and an operating team to match. The relaunch runs on two revenue engines: a Practitioner Channel — the acquired base moving to recurring system licences (BWS → FIELD), the miHealth device, and monthly Infoceutical wholesale — which carries the near-term revenue; and a Consumer Platform — the Beyond Medicine film → GEM app → GEM device → recurring Infoceuticals funnel — the longer-term moonshot. The film and a public beta app arrive this month (August 2026); the full commercial launch — sales team hired, every revenue stream live — is September 2026; the Salt Lake training weekend follows in early October. This document is the practical, quarter-by-quarter path to the v2.6 forecast — ≈ $2.7M (Q4 2026) → ≈ $16M (FY2027) → ≈ $134.7M (FY2031), EBITDA-positive from Q2 2027 — and to category leadership in energy-first wellness with a credible line to a $1B+ outcome. All product claims are structure/function and wellness only.

2. The three-year path to the forecast

The forecast is the arithmetic of two engines ramping on known unit economics. The three-year job is to prove the Practitioner Channel scales predictably, prove the Consumer funnel converts, and let the recurring mix compound.

At ~81–83% gross margin and a category-defining position, the FY2031 anchor supports an 8–10× revenue framing for a $1B+ outcome. Licensing revenue from cellular-field mapping is real upside and is deliberately not in these conservative numbers.

3. The one-year plan (Sep 2026 – Sep 2027)

Every workstream is a live project with a named owner and a written status file, tied to a revenue driver. The September launch bundles product, funnels, the sales hire and the supply-chain transition into one wave.

4. The next two quarters, in detail

Q3 2026 — August film + beta, then the September full launch

The wave lands in two beats. August: the Beyond Medicine documentary streams and the GEM app ships in public beta — top-of-funnel and product proof ahead of revenue. September: the full commercial launch — sales team hired, every revenue stream live. One coordinated launch: the film creates demand, the app and funnels capture it, the products and sales team convert it.

• Film — Beyond Medicine streams (Aug). Top-of-funnel; a practitioner-specific trailer feeds the B2B lane.
• Consumer app: beta (Aug) → public (Sep) + AI coach. Subscription gating, onboarding and critical-bug triage as a pre-launch gate; pricing Free 30-day → Member $10/mo → GEM plan $30/mo → Guided $90/mo (three Infoceuticals, three-month commitment).
• Practitioner sales team hired. Funnel baseline documented; 3–4 closers hired on draw-against-commission and script-certified; system sales open at ~10/mo; rent-to-own ($3,997 down + $397/mo) and miHealth ($5,000) selling. Tony Watson leads.
• Website & six funnels. e4l.com relaunches from the completed unified v2 package; build phases 0–5 release as Harry approves each gate.
• Cell Driver+ launch. The $38 hero SKU on sale with its Shopify store, label, SKU and landing page.
• GEM consumer. The GEM wearable on sale at $397, unlocking the GEM plan ($30/mo) and the "Your three" reorder cycle.
• miHealth. Device at $5,000; positioned as "in final-stage FDA OTC clearance for pain relief" (a regulatory status, not a treatment claim); no US "pain" claims pre-510(k).
• FIELD. BWS sells and is held stable while FIELD completes its build — FIELD ships Q2 2027, replacing BWS.
• Supply-chain transition. US OTC clearance secured ahead of launch; miHealth hardware fix into the next build; Infoceutical manufacturing at the Utah ISO facility (PRL); QC moved to the manufacturer; UK→US fulfilment planned with stock-runway analysis before cutover.

Q3 outcome: revenue starts in September; the Q4 2026 stub (Sep–Dec) tracks to ≈ $2.7M.

Q4 2026 — convert the wave, run the engine again

• Salt Lake training weekend (early October). The flywheel in one room — marketing fills the seats from the film/app wave, sales converts at the event. The repeatable film → app → event → practitioner engine: run it quarterly if it works. System sales step up to ~20/mo.
• FIELD build progresses toward its Q2 2027 launch — BWS remains the selling platform through the transition; rent-to-own economics unchanged.
• Consumer scale — Cell Driver+ ads scale; the "Your three" reorder cycle runs; the GEM consumer campaign (podcasts, paid) opens.
• Supply chain — the UK→US / EU / AUS fulfilment transition executed with no gap; per-country stock and global labelling set; run by the US Supply Chain Manager (already hired).
• Team — Matt Olaya (Director of Marketing) and the Controller (hired August 2026) in seat; account management stands up for onboarding and reorders.

Q4 outcome: Q4 2026 and Q1 2027 sit near breakeven; system sales reach ~30/mo by Mar 2027; the first EBITDA-positive quarter arrives at Q2 2027.

5. How we operate

E4L runs on a written, AI-assisted operating system — an efficiency differentiator, not the product and not the licensable IP — staged on one principle, visibility before automation. The reporting, finance and governance layers are live today: a git-repo system of record where AI drafts changes and humans approve; a Postgres warehouse holding the full CRM history; weekly team Wins/Focus/Help reports with a leadership analysis pass; automated monthly finance and commission reporting; the standing ≥15% net-profit discipline; Monday-board and repo reconciliation. The growth-intelligence layer — the 9-stage funnel dashboard and the weekly AI Growth Report, where an agent reads the metrics and drafts the narrative and humans decide — is being wired in over the next quarter. The effect: a small team executes and reports at a scale that normally needs a much larger one, with a monthly board KPI pack (active practitioners; system-sale run-rate; app downloads and paid subscribers; GEM units; Infoceutical reorder rate; MRR; CAC; sales funnel; gross margin; runway) that the bi-annual investor report draws from.

6. Milestones to the priced round

Instrument: a single $5M SAFE, prepared and opening for signature on completion of the charter formalities (August 2026), with rolling closes — $73M post-money cap + 15% discount, converting into the next priced round at the lower of the cap price or 85% of the round price. Accredited investors, mainly family offices; Reg D 506(c) — accredited status verified, not self-certified; Form D within 15 days of first close; full written disclosure via the Disclosure Memorandum every investor acknowledges. No escrow, no tranching. No super-voting shares.

Use of funds (growth-weighted, ~$5M): GEM inventory · FIELD/AI-platform completion and clinical research · consumer growth (funnels, app acquisition, Cell Driver+ and GEM campaigns) · operations and team.

• December 2026: film streaming, app public, e4l.com relaunched, Cell Driver+ and GEM selling, the sales team producing at ~20 system sales/mo, FIELD on track for its Q2 2027 launch, the training-weekend motion tested and ready to repeat. Q4 2026 stub revenue ≈ $2.7M.
• Mid-2027: system sales ~30/mo; FIELD launched (Q2 2027), replacing BWS and converting the base to recurring licences; two-plus quarters of consumer cohort data; the KPI pack showing FY2027 tracking to ≈ $16M with EBITDA positive from Q2 2027.
• Priced-round trigger: a priced round once (i) FY2027 revenue is demonstrably on the ≈$16M trajectory, (ii) the practitioner recurring and consumer cohorts show retention supporting the FY2028+ plan, and (iii) the acquired IP is securely vested in E4L. This SAFE is planned to carry the company to that round from a position of strength.